-
2023-506515-18-00
5
2020-10-23
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-506467-34-00
5
2020-10-20
Relapsing Multiple Sclerosis (MS)
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2023-506033-29-00
5
2020-10-09
EGFR Exon 20ins Mutated Locally
Advanced or Metastatic Non-Small Cell
-
2024-516481-11-00
5
2020-09-22
Metastatic Castration-Resistant Prostate Cancer
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-504974-40-00
4
2020-04-24
Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
-
2023-503500-87-00
11
2020-03-17
Muscle Invasive Bladder Cancer
-
2022-501012-34-00
5
2020-02-27
Pulmonary Arterial Hypertension
-
2022-501531-16-00
5
2020-01-24
esophageal carcinoma
-
2023-509908-15-00
10
2020-01-20
Mantle Cell Lymphoma
-
2023-507886-25-00
4
2019-09-27
Previously untreated and symptomatic patients with histologically prov
-
2023-508478-27-00
4
2019-07-30
Advanced stage Hodgkin Lymphoma
-
2023-504930-23-00
5
2019-07-19
Episodic Migraine
-
2023-509605-77-00
1
2019-06-27
Advanced solid tumours
-
2023-505477-33-00
5
2019-06-18
Psoriatic Arthritis
-
2023-505223-31-00
4
2019-06-14
Localized ER+ breast cancer
-
2024-511798-31-00
7
2019-05-31
KRAS p.G12C Mutant Advanced Solid Tumors
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2023-505478-14-00
5
2019-05-09
Psoriatic Arthritis
-
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
-
2023-509087-20-00
5
2019-04-16
Metastatic Castration-resistant Prostate Cancer